Kindred Biosciences to Announce First Quarter 2021 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, May 11, 2021. San Francisco, California (May 3, 2021) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 financial results on May 11, […]

Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy Indication

USDA approves the claim that the product is effective for the passive immunization of healthy dogs 13 weeks of age or older against canine parvovirus (CPV) disease Results demonstrated 100% efficacy against the deadly disease, highlighting the potential to address a critical unmet medical need San Francisco, California (April 28, 2021) – Kindred Biosciences, Inc. […]

Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study

San Francisco, California (April 20, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company’s novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that […]

Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results

San Francisco, California (March 16, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates on its programs. For the fourth quarter of 2020, KindredBio reported net revenues […]

Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, March 16, 2021. San Francisco, California (March 8, 2021) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and full year 2020 financial results […]